×

Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1

  • US 10,253,103 B2
  • Filed: 08/13/2018
  • Issued: 04/09/2019
  • Est. Priority Date: 08/13/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating non-insulin-dependent diabetes in a subject, comprising administering to the subject a therapeutically effective amount of a GLP-1 fusion protein comprising a GLP-1 and an antibody specifically binding to GLP-1R, wherein the antibody comprises:

  • heavy chain CDR1 amino acid sequence;

    SEQ ID NO;

    12, heavy chain CDR2 amino acid sequence;

    SEQ ID NO;

    19, heavy chain CDR3 amino acid sequence;

    SEQ ID NO;

    27, light chain CDR1 amino acid sequence;

    SEQ ID NO;

    37, light chain CDR2 amino acid sequence;

    SEQ ID NO;

    45, and light chain CDR3 amino acid sequence;

    SEQ ID NO;

    53.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×